EvoluteIQ raises funding led by Baird Capital to scale its agentic Artificial Intelligence platform

EvoluteIQ secured minority growth capital from Baird Capital to accelerate global expansion and advance its EIQ platform, which uses agentic Artificial Intelligence to automate complex, regulated business processes.

EvoluteIQ, a company founded in 2019, has secured minority growth capital from Baird Capital to accelerate global expansion and strengthen its position in enterprise-grade agentic Artificial Intelligence automation. The article does not state the size of the funding round. Baird Capital’s Daina Spedding and Mark Donnelly are set to join the EvoluteIQ board of directors, signalling a strategic partnership intended to support scaling and market growth.

The company develops the EIQ platform, built on its Agentic Mesh Architecture (aMa) and an AI Workbench, to orchestrate end-to-end workflows across sectors such as banking and financial services, insurance, healthcare, telecommunications, and manufacturing. EIQ combines process orchestration, data integration, and generative Artificial Intelligence-assisted decisioning within a single Low-Code/No-Code/Pro-Code environment, replacing fragmented toolchains and enabling teams to design, deploy, and scale AI-enabled business processes with improved speed, security, and cost efficiency.

Designed for complex, regulated organisations, the platform is used by some Fortune 500 enterprises to automate workflows and improve operational resilience. Sameet Gupte, co-founder and chief executive at EvoluteIQ, described the agentic Artificial Intelligence market as a shift from reactive automation to proactive, intelligent orchestration and noted that Baird Capital’s expertise and global resources will help accelerate the company’s growth. The funding is intended to support EvoluteIQ’s global expansion and to deepen its leadership in outcome-driven agentic models for enterprise automation.

72

Impact Score

CDC vaccine guidance meeting raises alarm

A Senate hearing and a pivotal advisory vote have exposed turmoil at the CDC over vaccine guidance, with former leaders warning that staff are being told to turn their backs on scientific evidence and advisers voting to stop recommending the MMRV vaccine for children under four.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.